Clinical Trial: Comparison of Sequential to Initial Combination Therapy in PAH

U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06968962) titled 'Comparison of Sequential to Initial Combination Therapy in PAH' on April 20.

Brief Summary: This is a multicenter, randomized, controlled, double-blind, and non-inferiority clinical trial to compare the efficacy of sequential to initial combination therapy in patients with pulmonary arterial hypertension (PAH). Ambrisentan and Tadalafil will be used in the study. Our research hypothesis is that the efficacy of sequential combination therapy in PAH patients is not inferior to the initial combination therapy as the primary efficacy endpoint is the change in 6MWD at month 12 from baseline.

Study Start Date: May, 2025

Study Type: INTER...